Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy - Wikidata - wikimedia - TriplyDB

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

http://www.wikidata.org/entity/Q27011473

about

sameAs

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations Lysophospholipid receptors in drug discovery.The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex Sphingosine-1-Phosphate Metabolism and Its Role in the Development of Inflammatory Bowel Disease Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3 The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.Lysophospholipid receptor nomenclature review: IUPHAR Review 8.FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.Dual functions of the trans-2-enoyl-CoA reductase TER in the sphingosine 1-phosphate metabolic pathway and in fatty acid elongation.ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation Prospective identification and purification of quiescent adult neural stem cells from their in vivo niche.Lysophosphatidic Acid signaling in the nervous system.Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway.Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling.B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.Sphingosine 1-phosphate receptors are essential mediators of eyelid closure during embryonic development Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis Mobilization of Peripheral Blood Stem Cells and Changes in the Concentration of Plasma Factors Influencing their Movement in Patients with Panic Disorder.

P2860

Q26740235-13B2325F-8DB8-4D2D-BE6A-3E479F33E03B Q26765300-5A027743-46A0-4D5A-A4CA-B60E6DDF137B Q27692680-230D2400-AB97-4D2E-BE53-7221D4A9C815 Q28073377-38FED622-729E-4B33-BC58-199B4E4231EF Q28085394-EBF917C1-FCB8-47BD-BB16-C818026C61A2 Q30235011-3CA7DA7B-6C05-4174-9A5C-488E1EECB6C5 Q30405763-D73828EE-62E5-4CA4-9F1B-E9786F82AB48 Q30486707-4CC63988-1B44-471D-90BC-157317BC4DB1 Q30838717-F08918F2-5686-4278-BC60-2BD5D6C25EEA Q30965003-AABA46C5-C072-4A59-BBF0-C40BDF325D65 Q33651898-224D6DFB-2AFC-4F37-854D-AAB508EA4DDC Q33755345-3E0EFDD8-400D-498E-8425-FE24DFADC181 Q33756197-154FCDD6-92ED-4881-AC03-0C3A99864DE3 Q33759830-7FC9152F-9BDB-44FA-AA35-7DC242E7BB3D Q33829582-A4BE7E09-4BFE-4535-BB86-EDC2DABA4266 Q33947251-8422D0B8-1512-4E76-B709-FA5347787DD6 Q34025135-22AC505C-8A2A-4D6C-AC22-AA912340963F Q34105944-3B626702-ADF8-4C93-9C89-657E9F69EA3A Q34138890-F12B800F-2AC6-4FDB-B16F-3A420B2B4A15 Q34408450-3543B6AB-6D4B-433C-9356-367220722772 Q34518822-9577B02E-1623-45DF-A862-97FF9DC53399 Q34999011-3E9E4329-9AF5-4283-B5DE-0FE2F1C1FF5F Q35180108-AB863724-BDE9-4CD5-861D-CA691C2FF8DE Q35456340-6DC5E95D-5B90-4A41-9346-DE5D5F27D24B Q35539166-0C936C80-98A2-435F-842F-F7128A687685 Q35572346-125151CA-70FD-4C68-ACC7-DA73E0DF00EB Q35659134-6BEAE8A8-A9C7-4093-AD8F-F0B4067688DF Q35666531-64F0C883-9288-4554-B928-834706687C65 Q35920281-C8342D8E-4F62-41DA-89F2-AF82F2C8554F Q35976992-95128B49-3E71-406E-97D6-4FA3615C1072 Q36154808-C929FCAC-2077-4665-8A81-A7977A915A28 Q36305638-6107B9C0-183D-4BB3-813B-F26F77B9B166 Q36330492-1F2BFCD1-4223-4FDF-9620-BA6BC825003B Q36991308-A85F2869-AA1A-49AB-9855-532313B36DB4 Q37093281-BF279498-33A1-437C-9B7F-3CAA8C312F27 Q37226246-4C7B62BA-7029-4BE6-9BC9-7007C70BCE94 Q37389500-195CB6EE-EC34-4C4F-9EC1-8AE1725F9492 Q37548170-B55A605F-0B81-4F97-BC2B-525E03608B02 Q37562917-C9E0D27C-C87C-4A86-9BD7-637B355F4375 Q37737570-007B6DB3-7EDC-4977-B7E2-44EAA6791DBE

P2860

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

http://www.wikidata.org/entity/Q27011473

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@ast

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@en

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@nl

type

label

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@ast

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@en

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@nl

prefLabel

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@ast

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@en

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@nl

P1433

Q27011473-61A01233-3A18-4511-AE16-E441E6C8CB80

P1476

Q27011473-68442723-35E1-4112-968D-B6B4C7B0816C

P2093

Q27011473-38A91A74-44E1-4AD3-89D8-5FA8FC09CF33

Q27011473-5B2AF8E7-4CA1-45BD-BB8E-9202CD2C04D9

Q27011473-88A13243-613B-448A-8E94-FB7A23039A1A

P2860

Q27011473-0115FCA0-882D-4AA4-A617-AE55130FCB9F

Q27011473-016E3A37-9720-4A5A-B6AA-13DFC86F2DF1

Q27011473-02C0DF65-3278-4B55-A61A-01C84F2918D0

Q27011473-035CF999-8BBB-434C-AE4B-37A00053408E

Q27011473-0441A80B-166E-4926-BC6B-84CDAB6E315C

Q27011473-05F1E8C5-21F0-4914-95BE-2E03ACD17F9E

Q27011473-0AC38DDC-9DFB-4E88-A451-469E8EC5D184

Q27011473-0AF4CF5E-81CE-4BF5-ABA9-64C42FF263B4

Q27011473-0E30BA50-6410-4FC3-88BB-1EF28D64A5F8

Q27011473-0E55D28C-7CEA-479D-9E11-5A5BFED3457B

P304

Q27011473-41233DAA-4E2D-40B1-9473-C615B37F9F90

P31

Q27011473-1580DA71-732F-4823-9C41-C42A64F3D985

P3181

Q27011473-DB8E007B-7441-4EF6-87C1-0FDAADDCBA26

P356

Q27011473-3757ED83-013B-4ED0-9232-F86A52B449A0

P407

Q27011473-1C2C6FE2-C364-4D3A-8DD2-A3D182C6F794

P433

Q27011473-2D4D004D-BD86-4413-90CC-E97EB48BA220

P478

Q27011473-6AA7609B-680D-432F-B4F4-E676147AEA65

P577

Q27011473-76612210-3CBC-423B-88AF-2DD9794175C7

P5875

Q27011473-AE4FC7F1-1AAC-4506-AD8E-301393B49B08

P698

Q27011473-2A023C55-5E1C-48AA-A7D5-C1E8FE1C526B

P921

Q27011473-00744C25-B4CB-4C84-84D8-C972360F6808

Q27011473-B72E9369-709A-484A-9633-692E71A076A6

Q27011473-E1859D6A-002B-4A6C-8131-A3D2F4C2A336

P932

Q27011473-F218220C-B1E6-4756-9099-D312CED5642D

P3181

P356

J.JNS.2013.02.011

P1433

Journal of the Neurological Sciences

P1476

Fingolimod: direct CNS effects ...... in multiple sclerosis therapy

@en

P2093

Aran Groves

http://www.w3.org/2001/XMLSchema#string

Jerold Chun

http://www.w3.org/2001/XMLSchema#string

Yasuyuki Kihara

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate

Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform

Dissecting demyelination

Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2

Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1

Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids

Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid

Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex

A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis

The astrocyte odyssey

P304

9-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

353488

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.JNS.2013.02.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

328

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236070345

http://www.w3.org/2001/XMLSchema#string

P698

23518370

http://www.w3.org/2001/XMLSchema#string

P921

FTY720-phosphate

multiple sclerosis

P932

3640626

http://www.w3.org/2001/XMLSchema#string